What is Retatrutide?
Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) is a 39-amino acid triple-receptor peptide. Triple receptor co-agonist simultaneously activating GLP-1R, GIPR, and GCGR. GCGR activation adds thermogenesis, fatty acid oxidation, and hepatic glucose production modulation beyond dual GIP+GLP-1 agonism. Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks (12mg dose).
Research Applications
Triple Receptor Pharmacology
GLP-1R + GIPR + GCGR co-agonism, additive receptor biology
GCGR Research
Isolated GCGR contribution vs tirzepatide (dual) in parallel arms
Obesity Models
Phase 2 NEJM 2023 reference — 24.2% weight reduction
Thermogenesis
GCGR-mediated fat oxidation and energy expenditure
NASH/Liver
Hepatic GCGR signalling and liver fat reduction
Quick Specs
| Form | Pre-filled cartridge (ready-to-use, no reconstitution) |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized |
| Molecular Formula | Large synthetic peptide (sequence-specific; proprietary) |
| Peptide Type | Triple Receptor Agonist (GLP-1 / GIP / Glucagon Receptors) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | 2–8°C refrigerated; do not freeze (21–28 days once in use) |
| Shelf Life | As indicated by manufacturer |
Certificate of Analysis (COA)
Cartridge-specific batch COAs are issued per production run. Email [email protected] with your order or SKU to receive the current Certificate of Analysis for this batch.

